| Abstract PO-013: Combined epigenetic therapy to induce latency II/III antigen expression in latency I EBV+ lymphoma IY Kong, VT Alonso, S Clark, S Sun, A Alonso, R Whitehouse, S Trezise, ... Blood Cancer Discovery 5 (3_Supplement), PO-013-PO-013, 2024 | | 2024 |
| Abstract PO-040: Mechanisms of action of immune checkpoint blockade therapy in EZH2/Bcl2-mutant B-cell lymphomas AV Sarapulov, S Inna, R Bucktrout, Y Isshiki, A Santella, MA Rodriguez, ... Blood Cancer Discovery 5 (3_Supplement), PO-040-PO-040, 2024 | | 2024 |
| Antibodies and methods of use thereof M Van Dijk, CA Mundt, G Ritter, D Schaer, JD Wolchok, T Merghoub, ... US Patent 11,993,653, 2024 | | 2024 |
| Abstract PO5-25-04: Predictive value of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in patients with triple negative breast cancer treated with pembrolizumab A Schreier, R Zappasodi, I Serganova, LM Arcos, XK Zhou, M Cristofanilli, ... Cancer Research 84 (9_Supplement), PO5-25-04-PO5-25-04, 2024 | | 2024 |
| Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment J Li, CR Chin, HY Ying, C Meydan, MR Teater, M Xia, P Farinha, K Takata, ... Nature Communications 15 (1), 2879, 2024 | | 2024 |
| Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma V Cancila, G Morello, G Bertolazzi, ASY Chan, G Bastianello, D Paysan, ... Research Square, 2024 | | 2024 |
| Mechanism of Action and Pharmacologic Features of Drugs Targeting PD‐1/PDL‐1 and CTLA‐4 MA Rodriguez, R Bucktrout, A Orlando, I Serganova, R Zappasodi Precision Cancer Therapies vol 2‐Immunologic Approaches for the Treatment of …, 2024 | | 2024 |
| APR-246 increases tumor antigenicity independent of p53 J Michels, D Venkatesh, C Liu, S Budhu, H Zhong, MM George, D Thach, ... Life Science Alliance 7 (1), 2024 | | 2024 |
| Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference F Gregucci, S Spada, MH Barcellos-Hoff, N Bhardwaj, C Chan Wah Hak, ... Oncoimmunology 12 (1), 2222560, 2023 | 1 | 2023 |
| Cd4+ tfh-like cells as a therapeutic target J Wolchok, R Zappasodi, T Merghoub US Patent App. 18/033,249, 2023 | | 2023 |
| 1444 Pharmacologic LDH inhibition redirects intratumoral glucose consumption and improves response to CTLA-4 blockade S Verma, R Zappasodi, S Budhu, I Serganova, L Dong, LM Mangarin, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 968 PD-1hiFoxp3-CD4+ tumor-infiltrating T-cell lineage commitment impacts the immunotherapy outcome LM Mangarin, S Martis, A Orlando, S Schad, JD Wolchok, B Greenbaum, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Modulating Treg stability to improve cancer immunotherapy JH Kang, R Zappasodi Trends in cancer 9 (11), 911-927, 2023 | 19 | 2023 |
| Anti-gitr antibodies and methods of use thereof O Leger, V Siebert, DM Van, D Schaer, T Tsuji, G Ritter, AM Gonzalez, ... | | 2023 |
| Enhancing T‐cell responses to GCB‐like lymphomas with immune‐checkpoint‐blockade‐based therapies. I Serganova, R Bucktrout, Y Isshiki, A Sarapulov, A Santella, M Rodriguez, ... Hematological Oncology 41, 2023 | | 2023 |
| LDH inhibition boosts effector T cells while destabilizing regulatory T cells and improves responses to CTLA-4 blockade S Verma, I Serganova, L Dong, S Budhu, L Mangarin, R Zappasodi, ... Cancer Research 83 (7_Supplement), 5873-5873, 2023 | | 2023 |
| Quantitative multiplex analysis of soluble and cellular immune checkpoint proteins in response to interferon gamma across multiple murine tumor models WR Lie, R Bucktrout, S Chakraborty, A Orlando, I Serganova, ... Cancer Research 83 (7_Supplement), 6381-6381, 2023 | | 2023 |
| Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy AL Garfall, AD Cohen, SP Susanibar-Adaniya, WT Hwang, DT Vogl, ... Blood Cancer Discovery 4 (2), 118-133, 2023 | 37 | 2023 |
| Anti-gitr antibodies and methods of use thereof AM Gonzalez, NS Wilson, DJ Underwood, V Seibert, O Léger, M Van Dijk, ... US Patent App. 17/808,248, 2023 | | 2023 |
| Factors Determining Long Term Anti-Tumor Responses to Immune Checkpoint Blockade Therapy A Taylor, G Cook, R Zappasodi Frontiers Media SA, 2023 | | 2023 |
Taha MerghoubAssociate Professor, MSK在 mskcc.org 的电子邮件经过验证
